Athenex said today that it inked a clinical collaboration deal to conduct a phase Ib study for its oral form of paclitaxel, Oraxol, with Eli Lilly‘s (NYSE:LLY) vascular endothelial growth factor (VEGF) receptor 2 antagonist, Cyramza. Patients with advanced gastric and esophageal cancer will be enrolled in 2017 at sites in the U.S. and Asia, where […]
